dermaliq – The Skin is our largest organ

The skin is our largest organ.

The skin is unique in many ways, but no other organ is so visible and demands so much attention and care in both diseased and healthy states.

About us

Dermaliq Therapeutics, Inc., is a venture-backed US specialty pharmaceutical company with operations in Heidelberg, Germany focusing on dermatology. Our mission is to develop breakthrough topical therapies and medical skin care products based on hyliQ^®, a unique, validated and proprietary enabling technology platform.

Dermaliq is designed to break new ground in hair loss treatments. Our lead asset DLQ01 aims to move topical hair loss treatments to a new level, by combining a validated prostaglandin class with a unique follicle targeted delivery platform.

THERAPEUTIC FOCUS

Breaking New Ground in Hair Loss Treatments

DLQ01 aims to move topical hair loss treatment beyond current treatment choices, by combining a validated drug class with a unique follicletargeted delivery platform.

Join us in tackling the root of the problem — literally in the follicle — and in bringing a truly new option to patients with female and male pattern hair loss.

Skin and hair disorders are a leading cause of nonfatal disease burden worldwide and have a significant impact on a person’s well-being, mental health, ability to function, and social participation.

Hair loss is also an unsolved problem in 2026 and ideal for topical treatments – in theory.

Approved drugs deliver modest gains. Response rates are low, especially in women
Minoxidil remains essentially the only approved topical option for female pattern hair loss, despite frequent discontinuation due to limited efficacy, side and convenience effects.

The central problem is delivery.

Hair follicles are mini organs that are hard to reach because of constant sebum outflow and the barrier of the stratum corneum.

Dermaliq developed hyliQ^®, an enabling technology that finally lets us use powerful molecules where they matter most: inside the follicle.

hyliQ^® is neither water based, nor oil based, nor a classic emulsion
It rapidly spreads, dries quickly, is non greasy and skin friendly, and penetrates deeply into glands and hair follicles, enabling targeted delivery.

The technology was initially developed for ophthalmology where it celebrates nowadays great success with more than 15 regulatory approvals around the world including USA, Europe and China.

Mechanistically, DLQ01 is designed to – wake-up the follicle and keep it growing.

it promotes hair growth and hair shaft production
the activation of follicular stem cells supports follicle regeneration and cycling
hyliQ^® is a fast drying, non-greasy, scalp friendly liquid, which is particularly important for women’s daily routines

Results from a randomized, blinded, vehicle and comparatorcontrolled trial in men with AGA are exciting:

83% of DLQ01treated subjects showed a positive hair growth response
>500% relative hair count improvement vs the vehicle
DLQ01 trended to be more efficacious than minoxidil 5%

The non-gender-specific mode-of-action makes DLQ01 uniquely positioned for women.

Technology

The evolutionary hyliQ^®– technology

hyliQ^®, the unique and proprietary technology owned by Dermaliq, is designed to provide cutaneous drug delivery with unmatched bioavailability for a wide range of pharmaceutical actives.

The technology enables the development of superior liquid therapeutic drugs and medical skin care products which are characterized by exceptional cosmetic properties.

hyliQ^® products do not require skin irritating excipients such as preservatives or penetration enhancers.

How it works

Proprietary hyliQ^® carrier molecules transport solubilized active ingredients through the stratum corneum, preferably into the epidermis, into glands, or into hair follicles. By selection of specific carrier molecules, we can customize the properties of our drug products, enhancing targeted penetration into the skin tissues, increasing efficacy and reducing unwanted side effects.

hyliQ^® – drug candidates

full dose is absorbed into skin and glands

Stratum Corneum

Epidermis

Dermis

Subcutaneous Tissue

Stratum Corneum

Epidermis

Dermis

Subcutaneous Tissue

Our Pipeline

hyliQ^® technology provides multiple development opportunities of next-generation topical drugs and medical skin care products.

DLQ01

Androgenetic Alopecia

DLQ01 aims to move topical hair loss treatment beyond current treatment choices, by combining a validated drug class with a unique follicle targeted delivery platform. This liquid topical formulation of a prostaglandin (PG) F2alpha analog in hyliQ^® is designed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern hair loss or baldness.

DLQ01 Phase 2 data in men delivered robust and meaningful clinical outcomes in this first-in-human trial. The number of hairs in the target area increased by >500% relative hair count improvement versus its vehicle. More than 80% of subjects responded with a positive change in hair growth. We are continuing clinical development focusing on Female Pattern Hair Loss based on robust scientific evidence and a clear regulatory pathway.

Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3

Androgenetic Alopecia DLQ01 aims to move topical hair loss treatment beyond current treatment choices, by combining a validated drug class with a unique follicle targeted delivery platform. This liquid topical formulation of a prostaglandin (PG) F2alpha analog in hyliQ^® is designed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern hair loss or baldness. DLQ01 Phase 2 data in men delivered robust and meaningful clinical outcomes in this first-in-human trial. The number of hairs in the target area increased by >500% relative hair count improvement versus its vehicle. More than 80% of subjects responded with a positive change in hair growth. We are continuing clinical development focusing on Female Pattern Hair Loss based on robust scientific evidence and a clear regulatory pathway.

DLQ01

DLQ02

Alopecia Areata
Alopecia Areata (AA) is a chronic immune-mediated condition affecting up to 2% of the global population.

It is characterized by autoimmune, chronic, and relapsing hair loss ranging from scattered patches to complete loss of hair, with significant psychological impact. At present, there are only two approved systemic drugs, which have a limited response rate. There is a high unmet medical need for safe topical applications, especially for mild and moderate forms of AA that only affect small areas of the scalp.

DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of immune-mediated conditions. DLQ02 offers a dual mode of action, combining immunomodulation with hirsutism, which promotes additional hair growth.

We plan to initiate a phase 2a study in Alopecia Areata by Q4/2024

Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3

Alopecia Areata Alopecia Areata (AA) is a chronic immune-mediated condition affecting up to 2% of the global population. It is characterized by autoimmune, chronic, and relapsing hair loss ranging from scattered patches to complete loss of hair, with significant psychological impact. At present, there are only two approved systemic drugs, which have a limited response rate. There is a high unmet medical need for safe topical applications, especially for mild and moderate forms of AA that only affect small areas of the scalp. DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of immune-mediated conditions. DLQ02 offers a dual mode of action, combining immunomodulation with hirsutism, which promotes additional hair growth. We plan to initiate a phase 2a study in Alopecia Areata by Q4/2024

DLQ02

DLQ03

Acceleration of wound healing and prevention of secondary skin infections

DLQ03 is a differentiated topical drug candidate, targeting accelerated wound healing and the prevention of secondary infections and to support the injured skin barrier. Burn wounds, but also artificial wounds after aesthetic procedures such as lasers, chemical peels, injections and surgery etc. are invasive and carry the risk of secondary infections and scarring.

DLQ03 Phase 2 data in human impressively demonstrated its superior efficacy in accelerating wound healing which was achieved 20-25% faster compared to vehicle.

Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3

Acceleration of wound healing and prevention of secondary skin infections DLQ03 is a differentiated topical drug candidate, targeting accelerated wound healing and the prevention of secondary infections and to support the injured skin barrier. Burn wounds, but also artificial wounds after aesthetic procedures such as lasers, chemical peels, injections and surgery etc. are invasive and carry the risk of secondary infections and scarring. DLQ03 Phase 2 data in human impressively demonstrated its superior efficacy in accelerating wound healing which was achieved 20-25% faster compared to vehicle.